Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502878-16-00

Enrollment

140

Registered

2023-07-12

Start date

2025-01-23

Completion date

Unknown

Last updated

2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic strokes with incomplete reperfusion

Brief summary

Early and late reperfusion

Detailed description

Degree of disability or dependence at 90+/-15 days as assessed by the mRS (shift analysis), Normalized change in NIHSS at 24+/- 6h post-randomization., Change in NIHSS at 90+/- 15 days post-randomization., Quality of life as assessed by the EuroQol 5D-3L at 90+/- 15 days, All-cause mortality at 90 days, No significant disability (i.e. mRS 0-1) at 90+/-15 days

Interventions

DRUGMetalyse 10

DRUG000 units. Powder and solvent for solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Early and late reperfusion	—

Secondary

Measure	Time frame
Degree of disability or dependence at 90+/-15 days as assessed by the mRS (shift analysis), Normalized change in NIHSS at 24+/- 6h post-randomization., Change in NIHSS at 90+/- 15 days post-randomization., Quality of life as assessed by the EuroQol 5D-3L at 90+/- 15 days, All-cause mortality at 90 days, No significant disability (i.e. mRS 0-1) at 90+/-15 days	—

Countries

Austria, Belgium, Finland, Germany, Netherlands, Portugal

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026